Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Abstract
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (11)
Dwight H. Owen
Nofisat Ismaila
American Society of Clinical Oncology (ASCO), Alexandria, VA, US
Amith Ahluwalia
Confluence Health Wenatchee Valley Hospital and Clinics, Wenatchee, WA
Jill Feldman
Patient Advocate EGFR Resisters Deerfield Illinois USA
Shirish Gadgeel
Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI
Michael Mullane
Aurora Cancer Care, Mount Pleasant, WI
Jarushka Naidoo
3Beaumont RCSI Cancer Centre, Dublin, Ireland
Carolyn J. Presley
Joshua E. Reuss
Georgetown University, Washington, DC
Eric K. Singhi
University of Texas MD Anderson Cancer Center, Houston, TX
Jyoti D. Patel
Tempus AI, Chicago, IL